Top

Diagnostic Pathology

Published in:

Open Access 01-12-2012 | Research

Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer

Authors: Sheng Wang, Sheng Xue, Yuanqing Dai, Jianfu Yang, Zhijun Chen, Xiwu Fang, Wensheng Zhou, Wei Wu, Qingwen Li

Published in: Diagnostic Pathology | Issue 1/2012

Abstract

Objective

MicroRNA-100 (miR-100) has been demonstrated to be downregulated in bladder cancer tissues, and enforced expression of this miRNA may inhibit cell growth and colony formation of human bladder cancer 5637 cells in vitro. However, the clinical significance of miR-100 in human bladder cancer has not yet been elucidated. Thus, the aim of this study was to investigate the diagnostic and prognostic values of miR-100 in this disease.

Methods

Expression levels of miR-100 in 126 pairs of bladder cancer and adjacent normal tissues were detected by TaqMan real-time quantitative RT-PCR assay. In order to determine its prognostic value, overall survival (OS) and progression-free survival (PFS) were evaluated using the Kaplan-Meier method, and multivariate analysis was performed using the Cox proportional hazard analysis.

Results

Expression levels of miR-100 in bladder cancer tissues were significantly lower than those in adjacent normal tissues (mean expression level: 2.6 ± 1.2 vs. 3.9 ± 1.5, P < 0.001). When categorized into low vs. high expression, low miR-100 expression was negatively associated with the stage (P = 0.01), the recurrence (P = 0.008), the progression (P = 0.01), and the death (P < 0.001) of patients with bladder cancer. Moreover, low miR-100 expression clearly predicted poorer PFS (P = 0.001) and OS (P < 0.001). In the multivariate analysis, low miR-100 expression was an independent prognostic factor for both PFS (P = 0.01) and OS (P = 0.008).

Conclusion

Our data offer the convincing evidence that miR-100 may play an important role in the progression of bladder cancer and that the reduced expression of this miRNA may be independently associated with shorter PFS and OS of patients, suggesting that miR-100 might be a potential marker for further risk stratification in the treatment of this cancer.

Virtual slides

The virtual slides’ for this article can be found here:http://www.diagnosticpathology.diagnomx.eu/vs/1105483419841671

Available only for authorised users

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 2009, 59: 225-249. 10.3322/caac.20006.CrossRefPubMed

Droller MJ: Bladder cancer: state-of-the-art care. CA Cancer J Clin. 1998, 48: 269-284. 10.3322/canjclin.48.5.269.CrossRefPubMed

Vaishampayan U: Systemic therapy of advanced urothelial cancer. Curr Treat Options Oncol. 2009, 10: 256-266. 10.1007/s11864-009-0101-9.CrossRefPubMed

Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG: Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol. 2001, 19: 666-675.PubMed

Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Lieskovsky G, Quinn DI, Raghavan D, Skinner DG: Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer. 2003, 98: 955-961. 10.1002/cncr.11569.CrossRefPubMed

Khaled HM, Bahnassi AA, Zekri AR, Kassem HA, Mokhtar N: Correlation between p53 mutations and HPV in bilharzial bladder cancer. Urol Oncol. 2003, 21: 334-341. 10.1016/S1078-1439(03)00014-0.CrossRefPubMed

Bahadir B, Behzatoglu K, Bektas S, Bozkurt ER, Ozdamar SO: CD10 expression in urothelial carcinoma of the bladder. Diagn Pathol. 2009, 4: 38-10.1186/1746-1596-4-38.PubMedCentralCrossRefPubMed

Yildiz IZ, Recavarren R, Armah HB, Bastacky S, Dhir R, Parwani AV: Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsies. Diagn Pathol. 2009, 4: 35-10.1186/1746-1596-4-35.PubMedCentralCrossRefPubMed

Wang M, Chu H, Li P, Yuan L, Fu G, Ma L, Shi D, Zhong D, Tong N, Qin C, Yin C, Zhang Z: Genetic variants in microRNAs predict bladder cancer risk and recurrence. Cancer Res. 2012, In press

10.

Williams MB, Liana A: MicroRNAs in Bladder Cancer. MicroRNAs in Cancer Translational Research. Edited by: Cho WCS. 2011, Netherlands: Springer Netherlands, 223-237.CrossRef

11.

Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM: MicroRNA expression and function in cancer. Trends Mol Med. 2006, 12: 580-587. 10.1016/j.molmed.2006.10.006.CrossRefPubMed

12.

Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004, 101: 2999-3004. 10.1073/pnas.0307323101.PubMedCentralCrossRefPubMed

13.

Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T: MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 2011, 59: 671-681. 10.1016/j.eururo.2011.01.044.CrossRefPubMed

14.

Song T, Xia W, Shao N, Zhang X, Wang C, Wu Y, Dong J, Cai W, Li H: Differential miRNA expression profiles in bladder urothelial carcinomas. Asian Pac J Cancer Prev. 2010, 11: 905-911.PubMed

15.

Oliveira JC, Brassesco MS, Morales AG, Pezuk JA, Fedatto PF, da Silva GN, Scrideli CA, Tone LG: MicroRNA-100 acts as a tumor suppressor in human bladder carcinoma 5637 cells. Asian Pac J Cancer Prev. 2011, 12: 3001-3004.PubMed

16.

Torres A, Torres K, Pesci A, Ceccaroni M, Paszkowski T, Cassandrini P, Zamboni G, Maciejewski R: Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma. BMC Cancer. 2012, 12: 369-10.1186/1471-2407-12-369.PubMedCentralCrossRefPubMed

17.

Feng B, Wang R, Chen LB: MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett. 2012, 317: 184-191. 10.1016/j.canlet.2011.11.024.CrossRefPubMed

18.

Li BH, Zhou JS, Ye F, Cheng XD, Zhou CY, Lu WG, Xie X: Reduced miR-100 expression in cervical cancer and precursors and its carcinogenic effect through targeting PLK1 protein. Eur J Cancer. 2011, 47: 2166-2174. 10.1016/j.ejca.2011.04.037.CrossRefPubMed

19.

Li X, Zhang Y, Zhang H, Liu X, Gong T, Li M, Sun L, Ji G, Shi Y, Han Z, Han S, Nie Y, Chen X, Zhao Q, Ding J, Wu K: Daiming F: miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res. 2011, 9: 824-833. 10.1158/1541-7786.MCR-10-0529.CrossRefPubMed

20.

Zeng Y, Qu X, Li H, Huang S, Wang S, Xu Q, Lin R, Han Q, Li J, Zhao RC: MicroRNA-100 regulates osteogenic differentiation of human adipose-derived mesenchymal stem cells by targeting BMPR2. FEBS Lett. 2012, 586: 2375-2381. 10.1016/j.febslet.2012.05.049.CrossRefPubMed

21.

Petrelli A, Perra A, Schernhuber K, Cargnelutti M, Salvi A, Migliore C, Ghiso E, Benetti A, Barlati S, Ledda-Columbano GM, Portolani N, De Petro G, Columbano A, Giordano S: Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. Oncogene. 2012, 31: 4517-4526. 10.1038/onc.2011.631.CrossRefPubMed

22.

Zheng YS, Zhang H, Zhang XJ, Feng DD, Luo XQ, Zeng CW, Lin KY, Zhou H, Qu LH, Zhang P, Chen YQ: MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia. Oncogene. 2012, 31: 80-92. 10.1038/onc.2011.208.PubMedCentralCrossRefPubMed

23.

Peng DX, Luo M, Qiu LW, He YL, Wang XF: Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer. Oncol Rep. 2012, 27: 1238-1244.PubMedCentralPubMed

24.

Bai J, Guo A, Hong Z, Kuai W: Upregulation of microRNA-100 predicts poor prognosis in patients with pediatric acute myeloid leukemia. Oncol Targets Ther. 2012, 5: 213-219.

25.

Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Sañudo A, Camara-Lopes LH, Srougi M: MicroRNA expression profiles in the progression of prostate cancer-from high-grade prostate intraepithelial neoplasia to metastasis. Urol Oncol. 2011, In press

26.

Dai Y, Xie CH, Neis JP, Fan CY, Vural E, Spring PM: MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck. 2011, 33: 786-791. 10.1002/hed.21540.CrossRefPubMed

27.

Ng WL, Yan D, Zhang X, Mo YY, Wang Y: Over-expression of miR-100 is responsible for the low-expression of ATM in the human glioma cell line: M059J. DNA Repair (Amst). 2010, 9: 1170-1175. 10.1016/j.dnarep.2010.08.007.CrossRef

28.

Henson BJ, Bhattacharjee S, O’Dee DM, Feingold E, Gollin SM: Decreased expression of miR-125b and miR-100 in oral cancer cells contributes to malignancy. Genes Chromosomes Cancer. 2009, 48: 569-582. 10.1002/gcc.20666.PubMedCentralCrossRefPubMed

Title: Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer
Authors: Sheng Wang
Sheng Xue
Yuanqing Dai
Jianfu Yang
Zhijun Chen
Xiwu Fang
Wensheng Zhou
Wei Wu
Qingwen Li
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Diagnostic Pathology / Issue 1/2012
Electronic ISSN: 1746-1596
DOI: https://doi.org/10.1186/1746-1596-7-159

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer

Abstract

Objective

Methods

Results

Conclusion

Virtual slides

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Virtual slides

Please log in to get access to this content

Other articles of this Issue 1/2012

Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer

Validation of diagnostic accuracy using digital slides in routine histopathology

Methods of Improving Speech Intelligibility for Listeners with Hearing Resolution Deficit

Colloid cyst of the third ventricle, hypothalamus, and heart: a dangerous link for sudden death

Histological and immunohistochemical features of the spleen in persistent polyclonal B-cell lymphocytosis closely mimic splenic B-cell lymphoma

Pleomorphic lipoma lacking mature fat component in extensive myxoid stroma: a great diagnostic challenge